Logo

Abivax Reports One-Year Maintenance Results of ABX464 in P-IIa Trial for the Treatment with Rheumatoid Arthritis

Share this
Abivax Reports One-Year Maintenance Results of ABX464 in P-IIa Trial for the Treatment with Rheumatoid Arthritis

Abivax Reports One-Year Maintenance Results of ABX464 in P-IIa Trial for the Treatment with Rheumatoid Arthritis

Shots:

  • The P-IIa maintenance trial evaluates ABX464 (50mg, qd) + methotrexate (MTX) in 40 patients with RA after 1yr. of continued treatment
  • The results showed that 23 out of 40 patients reached the 1yr. of treatment & 100% achieved an ACR20 response which translates into 58% in the FAS @52wks. of treatment, 57% of the patients were in remission as assessed by the DAS28-CRP corresponding to 33% using the full analysis set (FAS)
  • In the observed population, 83% & 52% achieved ACR50 & ACR70 response corresponding to 48% & 30% in the FAS, 17 patients discontinued the study due to AEs @1yr. of maintenance treatment. The safety profile was favorable and consistent with previous observations

Ref: Accesswire | Image: Businesswire

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions